Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | XFRA CAPITAL ADJUSTMENT INFORMATION - 26.07.2024 | 88 | Xetra Newsboard | Das Instrument 1NN ES0105251005 NEINOR HOMES SA EO 8,21 EQUITY wird cum Kapitalmassnahme gehandelt am 26.07.2024 und ex Kapitalmassnahme am 29.07.2024 The instrument 1NN ES0105251005 NEINOR HOMES SA... ► Artikel lesen | |
Di | CYXONE: The board decides on a rights issue of a maximum of approximately SEK 23 million to finance continued development of rabeximod and T20K | 4 | Cision News | ||
15.07. | Cyxone provides an update on its research and development program | 2 | Cision News | ||
22.04. | Kjell Stenberg new CEO in Cyxone AB | 4 | Cision News | ||
28.03. | Cyxone comments on the clinical collaboration in the UK | 6 | Cision News | ||
25.03. | Cyxone enters important research collaboration | 4 | Cision News | ||
05.03. | Cyxone's CEO gives a status update | 7 | Cision News | ||
11.12.23 | Nasdaq Stockholm AB: Last day of trading in paid subscription shares (BTA) of Cyxone AB (651/23) | 282 | GlobeNewswire | Trading in Cyxone AB paid subscription shares is to cease. The last trading day
is December 12, 2023.
Short name: CYXO BTA
---------------------------
ISIN code: SE0021020450
---------------------------
Orderbook... ► Artikel lesen | |
07.11.23 | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Cyxone AB | 400 | GlobeNewswire | With effect from November 08, 2023, the subscription rights in Cyxone AB will
be traded on First North Growth Market. Trading will continue up until and
including November 16, 2023.
Instrument: ... ► Artikel lesen | |
01.11.23 | XFRA CAPITAL ADJUSTMENT INFORMATION - 01.11.2023 | 718 | Xetra Newsboard | Das Instrument 7RT FI0009006951 VALOE OYJ EQUITY wird ex Kapitalmassnahme gehandelt am 01.11.2023 The instrument 7RT FI0009006951 VALOE OYJ EQUITY is traded ex capital adjustment on 01.11.2023Das Instrument... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 79,10 | 0,00 % | BioNTech SE: BioNTech veröffentlicht am 5. August 2024 Ergebnisse für das zweite Quartal 2024 und informiert über operativen Fortschritt | MAINZ, Deutschland, 22. Juli 2024(Nasdaq: BNTX, "BioNTech" oder "das Unternehmen") wird am Montag, den 5. August 2024, die Ergebnisse für das zweite Quartal 2024 veröffentlichen. Darüber hinaus wird... ► Artikel lesen | |
VALNEVA | 3,292 | +0,12 % | Valneva-Aktie +6%: Das bringt neuen Schwung | Nach einer scharfen Korrektur am Freitag springt die Valneva-Aktie (WKN: A0MVJZ) am Montagmorgen um knapp +6% auf 3,48€. Eine bedeutende Finanzspritze sorgt für neue Impulse. Kann der Biotech-Titel... ► Artikel lesen | |
NOVAVAX | 15,736 | -0,18 % | Market Whales and Their Recent Bets on NVAX Options | ||
AETERNA ZENTARIS | 4,910 | -0,81 % | Aeterna Zentaris Inc: Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders | TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing... ► Artikel lesen | |
BAVARIAN NORDIC | 23,990 | +0,59 % | Bavarian Nordic: "Exponentieller Anstieg" von Mpox-Fällen | In Afrika breiten sich Mpox (vormals bekannt unter Affenpocken) weiter aus. Die Regierung Demokratischen Republik Kongo berichtete laut übereinstimmenden Medienberichten am Samstag über einen "exponentiellen... ► Artikel lesen | |
BELLEROPHON THERAPEUTICS | 0,001 | 0,00 % | Bellerophon Therapeutics, Inc. - 15-12G, Securities registration termination | ||
PHIO PHARMACEUTICALS | 3,440 | 0,00 % | Phio Pharmaceuticals Corp. - S-1, General form for registration of securities | ||
ORAGENICS | 1,040 | +2,97 % | ORAGENICS INC - 8-K, Current Report | ||
LEXICON PHARMACEUTICALS | 2,104 | -4,28 % | Lexicon Pharmaceuticals, Inc.: Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024 | ||
CSTONE PHARMACEUTICALS | 0,137 | -3,52 % | CStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer | Sugemalimab becomes the world's first anti-PD-L1 monoclonal antibody (mAb) approved in Europe for first-line treatment of both squamous and non-squamous non-small cell lung cancer (NSCLC)... ► Artikel lesen | |
OUTLOOK THERAPEUTICS | 7,750 | -1,90 % | Outlook Therapeutics, Inc.: Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD | UK MHRA marketing authorization follows recent European Commission Marketing Authorization for LYTENAVA (bevacizumab gamma) in the EU for the treatment of wet AMDInitial commercial launches of LYTENAVA... ► Artikel lesen | |
NANOSPHERE HEALTH SCIENCES | 0,028 | 0,00 % | The Morning After: 'Nanosphere' paint could reduce a plane's CO2 emissions | ||
GENSCRIPT BIOTECH | 1,440 | 0,00 % | GENSCRIPT BIO (01548): PROFIT ALERT - ESTIMATED REDUCTION IN LOSS | ||
KRYSTAL BIOTECH | 200,50 | +1,96 % | Krystal Biotech, Inc.: Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024 | ||
LEAP THERAPEUTICS | 2,100 | +3,96 % | Leap Therapeutics, Inc.: Leap Therapeutics Reports First Quarter 2024 Financial Results | CAMBRIDGE, Mass., May 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial... ► Artikel lesen |